Oramed Pharmaceuticals Inc.

NasdaqCM:ORMP Stock Report

Market Cap: US$97.6m

Oramed Pharmaceuticals Management

Management criteria checks 3/4

Oramed Pharmaceuticals' CEO is Nadav Kidron, appointed in Mar 2006, has a tenure of 18.83 years. total yearly compensation is $1.66M, comprised of 27.9% salary and 72.1% bonuses, including company stock and options. directly owns 3.18% of the company’s shares, worth $3.10M. The average tenure of the management team and the board of directors is 12.1 years and 8.3 years respectively.

Key information

Nadav Kidron

Chief executive officer

US$1.7m

Total compensation

CEO salary percentage27.9%
CEO tenure18.8yrs
CEO ownership3.2%
Management average tenure12.1yrs
Board average tenure8.3yrs

Recent management updates

Recent updates

Here's Why We're Not Too Worried About Oramed Pharmaceuticals' (NASDAQ:ORMP) Cash Burn Situation

Aug 24
Here's Why We're Not Too Worried About Oramed Pharmaceuticals' (NASDAQ:ORMP) Cash Burn Situation

Oramed Pharmaceuticals (NASDAQ:ORMP) Is In A Good Position To Deliver On Growth Plans

May 03
Oramed Pharmaceuticals (NASDAQ:ORMP) Is In A Good Position To Deliver On Growth Plans

Companies Like Oramed Pharmaceuticals (NASDAQ:ORMP) Are In A Position To Invest In Growth

Dec 22
Companies Like Oramed Pharmaceuticals (NASDAQ:ORMP) Are In A Position To Invest In Growth

Oramed: Oral Insulin For Type 2 Diabetes May Become A Reality

Sep 21

Oramed to hand Korean rights for insulin capsule

Sep 09

Oramed to report early-stage trial data for oral COVID-19 shot in 3Q

Jul 07

Is Oramed Pharmaceuticals (NASDAQ:ORMP) In A Good Position To Invest In Growth?

Jun 12
Is Oramed Pharmaceuticals (NASDAQ:ORMP) In A Good Position To Invest In Growth?

Oramed And Oral Insulin: Can This Small Company Really Do It?

Apr 14

Companies Like Oramed Pharmaceuticals (NASDAQ:ORMP) Are In A Position To Invest In Growth

Feb 23
Companies Like Oramed Pharmaceuticals (NASDAQ:ORMP) Are In A Position To Invest In Growth

Oramed And The Hurdles Of Developing Oral Insulin

Dec 23

Here's Why We're Not Too Worried About Oramed Pharmaceuticals' (NASDAQ:ORMP) Cash Burn Situation

Nov 02
Here's Why We're Not Too Worried About Oramed Pharmaceuticals' (NASDAQ:ORMP) Cash Burn Situation

Oramed: Prospects Still Remain Despite Merck-Ridgeback's Progress

Oct 04

We Think Shareholders Will Probably Be Generous With Oramed Pharmaceuticals Inc.'s (NASDAQ:ORMP) CEO Compensation

Aug 24
We Think Shareholders Will Probably Be Generous With Oramed Pharmaceuticals Inc.'s (NASDAQ:ORMP) CEO Compensation

Oramed Pharmaceuticals (NASDAQ:ORMP) Is In A Good Position To Deliver On Growth Plans

Jul 21
Oramed Pharmaceuticals (NASDAQ:ORMP) Is In A Good Position To Deliver On Growth Plans

Oramed reaches 50% enrollment in late-stage oral insulin study

Jun 08

Oramed Pharmaceuticals (NASDAQ:ORMP) Is In A Good Position To Deliver On Growth Plans

Apr 06
Oramed Pharmaceuticals (NASDAQ:ORMP) Is In A Good Position To Deliver On Growth Plans

CEO Compensation Analysis

How has Nadav Kidron's remuneration changed compared to Oramed Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

US$4m

Jun 30 2024n/an/a

US$21m

Mar 31 2024n/an/a

US$10m

Dec 31 2023US$2mUS$463k

US$6m

Sep 30 2023n/an/a

-US$16m

Jun 30 2023n/an/a

-US$20m

Mar 31 2023n/an/a

-US$30m

Dec 31 2022US$7mUS$491k

-US$37m

Sep 30 2022n/an/a

-US$46m

Jun 30 2022n/an/a

-US$46m

Mar 31 2022n/an/a

-US$40m

Dec 31 2021n/an/a

-US$35m

Nov 30 2021n/an/a

-US$25m

Aug 31 2021US$4mUS$466k

-US$22m

May 31 2021n/an/a

-US$18m

Feb 28 2021n/an/a

-US$15m

Dec 31 2020n/an/a

-US$22m

Nov 30 2020n/an/a

-US$15m

Aug 31 2020US$2mUS$439k

-US$12m

May 31 2020n/an/a

-US$11m

Feb 29 2020n/an/a

-US$13m

Nov 30 2019n/an/a

-US$13m

Aug 31 2019US$2mUS$419k

-US$14m

May 31 2019n/an/a

-US$15m

Feb 28 2019n/an/a

-US$15m

Nov 30 2018n/an/a

-US$14m

Aug 31 2018US$2mUS$436k

-US$13m

Compensation vs Market: Nadav's total compensation ($USD1.66M) is above average for companies of similar size in the US market ($USD649.25K).

Compensation vs Earnings: Nadav's compensation has been consistent with company performance over the past year.

CEO

Nadav Kidron (50 yo)

18.8yrs

Tenure

US$1,659,222

Compensation

Mr. Nadav Kidron, Esq. has been the Chief Executive Officer and President of Oramed Pharmaceuticals Inc. (Alternatively Integrated Security Technologies Inc) since March 08, 2006. Mr. Kidron served as an i...

Leadership Team

NamePositionTenureCompensationOwnership
Nadav Kidron
President18.8yrsUS$1.66m3.18%
$ 3.1m
Miriam Kidron
Chief Scientific Officer & Director18.8yrsUS$1.11m1.07%
$ 1.0m
Avraham Gabay
CFO, Treasurer & Secretaryless than a yearUS$1.05m0.074%
$ 72.6k
Joshua Hexter
Chief Operating & Business Officer5.3yrsUS$1.28m0.76%
$ 745.4k

12.1yrs

Average Tenure

52yo

Average Age

Experienced Management: ORMP's management team is seasoned and experienced (12.1 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Nadav Kidron
President18.8yrsUS$1.66m3.18%
$ 3.1m
Miriam Kidron
Chief Scientific Officer & Director18.8yrsUS$1.11m1.07%
$ 1.0m
Jay Skyler
Member of Scientific Advisory Board5yrsno datano data
Eleuterio Ferrannini
Member of Scientific Advisory Board17.9yrsno datano data
Harold Jacob
Member of Scientific Advisory Board8.2yrsUS$20.00kno data
Avram Hershko
Member of Scientific Advisory Board16.5yrsno datano data
G. Alexander Fleming
Member of Scientific Advisory Board5.1yrsno datano data
Leonard Sank
Independent Director17.3yrsUS$112.28k0.081%
$ 78.7k
Roy Eldor
Member of the Scientific Advisory Board8.5yrsno datano data
Anne Peters
Member of Scientific Advisory Board2.6yrsno datano data
Arie Mayer
Independent Director5.1yrsUS$127.28k0.076%
$ 74.2k
Julio Rosenstock
Member of Scientific Advisory Board5yrsno datano data

8.3yrs

Average Tenure

70yo

Average Age

Experienced Board: ORMP's board of directors are considered experienced (8.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/02 06:53
End of Day Share Price 2025/01/02 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Oramed Pharmaceuticals Inc. is covered by 8 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Andrew D'SilvaB. Riley Securities, Inc.
Edward NashCanaccord Genuity
Charles DuncanCantor Fitzgerald & Co.